Basilea Pharmaceutica company profile
Company profile
Basilea Pharmaceutica has 200 employees and is headquartered in Allschwil, Switzerland.
Anti-infective medicines are the core of Basilea Pharmaceutica AG's business, which develops and sells treatments for serious bacterial and fungal infections. Its marketed products are Cresemba, an antifungal given intravenously or orally, and Zevtera, a ceftobiprole-based antibiotic used for pneumonia, Staphylococcus aureus bacteremia and skin infections. The pipeline includes fosmanogepix, a broad-spectrum antifungal for mold infections, and ceftibuten-ledaborbactam etzadroxil, an oral antibiotic for complicated urinary tract infections. The company also works with Prokaryotics, Inc on antifungals against drug-resistant pathogens and with Phare Bio on generative AI for antibiotic discovery.
In the fiscal year ended December 2025, revenue reached CHF 232.4 million, up 11.4% from the previous year, and net income was CHF 40.2 million. The company, founded in 2000, is headquartered in Allschwil, Switzerland, and employs 200 people.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Headquarters
- Hegenheimermattweg 167b, 4123, Allschwil
- Employees
- 200
- Chief executive
- David Veitch
- Founded
- 2000
- Fiscal year
- January - December
- Listing
- BSLN · SIX
- Currency
- CHF
- ISIN
- CH0011432447
- Website
- basilea.com
Basilea Pharmaceutica and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
| Pharma MarPHM | Spain | $1.1B | 505 | 21.3% | 14.7 |
| IdorsiaIDIA | Switzerland | $1.26B | 424 | -68.4% | — |
| PhilogenPHIL | Italy | $905.96M | 230 | 79.1% | 3.67 |
| InventivaIVA | France | $890.8M | 87 | -5,980.9% | — |
| Pharming GroupPHARM | Netherlands | $841.25M | 407 | 12.8% | 36.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
